| Description |
1 online resource (xxi, 642 pages) : illustrations (chiefly color) |
| Contents |
Part I: Basic principles and methods. Introduction to predictive biomarkers: definitions and characteristics -- Introduction to clinical trials, clinical trial designs, and statistical terminology used for predictive biomarker research and validation -- Overview of methods used in predictive biomarker studies in a molecular anatomic pathology laboratory -- Significance of immunohistochemistry and in situ hybridization techniques for predictive biomarker studies -- Overview of PCR-based technologies and multiplexed gene analysis for biomarker studies -- Introduction to microarray technology -- Digital and computational pathology for biomarker discovery -- Detection of predictive biomarkers using liquid biopsies -- Measurement of predictive cancer biomarkers by flow cytometry -- Personalized cancer treatment and patient stratification using massive parallel sequencing (MPS) and other omics data -- Bioinformatic methods and resources for biomarker discovery, validation, development, and integration -- Part II: Major cell signaling pathways. Overview of cell signaling pathways in cancer -- Steroid hormone and nuclear receptor signaling pathways -- Protein kinase c signaling in carcinogenesis -- Roles of Rho/ROCK in cancer signaling -- Mitogen-activated protein kinase (MAPK) signaling -- Notch signaling pathway in carcinogenesis -- Signaling of the ErbB receptor family in carcinogenesis and the development of targeted therapies -- Angiogenic signaling pathways and anti-angiogenic therapies in human cancer -- Role of PI3K/AKT/mTOR in cancer signaling -- Met signaling in carcinogenesis -- Role of insulin-like growth factor receptors in cancer signaling -- Role of Wnt/[beta]-catenin pathway in cancer signaling -- Hedgehog signaling in carcinogenesis -- TGF-[beta] and the SMAD signaling pathway in carcinogenesis -- Role of JAK-STAT pathway in cancer signaling -- NF-[kappa]B signaling pathways in carcinogenesis -- Immune signaling in carcinogenesis -- Predictive biomarkers and targeted therapies in immuno-oncology -- Role of protein tyrosine phosphatases in cancer signaling |
|
Part III: Predictive biomarkers in specific organs. Predictive and prognostic biomarkers in myeloid neoplasms -- Predictive biomarkers and targeted therapies for lymphoid malignancies -- Targeted therapies for pediatric central nervous system tumors -- Predictive biomarkers and targeted therapies in adult brain cancers -- Predictive biomarkers and targeted therapies in breast cancer -- Predictive biomarkers in lung cancer -- Predictive biomarkers and targeted therapies in genitourinary cancers -- Predictive biomarkers and targeted therapies in colorectal cancer -- Predictive markers and targeted therapies in gastroesophageal cancer (GEC) -- Predictive biomarkers and targeted therapies in hepatic, pancreatic, and biliary cancers -- Predictive biomarkers and targeted therapies in gynecological cancers -- Predictive biomarkers and targeted therapies in head and neck cancer -- Predictive biomarkers and targeted therapies in the skin -- Predictive biomarkers and targeted therapies in sarcomas -- Predictive markers and targeted therapies in thyroid cancer and selected endocrine tumors -- The response evaluation criteria in solid tumors (RECIST) -- Part IV: Regulatory processes, quality and policy issues, companion diagnostics, and role of central laboratories. IVDs and FDA marketing authorizations: a general overview of FDA approval process of an IVD companion diagnostic device in oncology -- Quality control of immunohistochemical and in situ hybridization predictive biomarkers for patient treatment: experience from international guidelines and international quality control schemes -- Use of companion diagnostics (CDx) and predictive biomarkers for cancer targeted therapy: clinical applications in precision medicine -- Policy issues in the clinical development and use of predictive biomarkers for molecular targeted therapies -- Role of central laboratories in research, validation, and application of predictive biomarkers -- Part V: Precision medicine clinical trials and FDA-approved targeted therapies -- Prominent precision medicine clinical trials in oncology around the world -- Precision medicine clinical trials: successes and disappointments, challenges and opportunities--lessons learnt -- FDA-approved targeted therapies in oncology |
| Summary |
"'Precision/personalized or stratified medicine' refers to the tailoring of medical treatment or drug administration to the individual characteristics of each patient treatment. It does not literally mean that a pharmaceutical company makes a drug for an individual patient for consumption and treatment but rather means the ability to stratify (or classify) individuals into sub-populations that differ in their responsiveness to a specific drug. A marker that provides information on the likely response to therapy, i.e., either in terms of tumor shrinkage or survival of the patient is termed "predictive biomarker". Despite their promise in precision medicine and the explosion of knowledge in this area, there is not a single source on this subject that puts all this evidence together in a concise or richly illustrated and easy to understand manner. This book provides a collection of ingeniously organized, well-illustrated and up-to-date authoritative chapters divided into five sections that are clear and easy to understand. Throughout the book, sidebars, special interest boxes and illustrations are used to explain terms that are either newly introduced, uncommon, or specialized. Predictive Biomarkers in Oncology will serve as a definitive guide for practicing pathologists, oncologists, basic researchers, and personnel in the pharmaceutical or diagnostic industry interested in learning how "predictive biomarkers" are used in precision cancer therapy"--Publisher's description |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Online resource; title from resource home page (ProQuest Ebook Central, viewed January 16, 2020) |
| In |
Springer eBooks |
| Subject |
Cancer -- Molecular diagnosis.
|
|
Biochemical markers.
|
|
Oncology.
|
|
Biomarkers, Tumor -- analysis
|
|
Neoplasms -- diagnosis
|
|
Biomarkers
|
|
In Situ Hybridization -- methods
|
|
Immunohistochemistry -- methods
|
|
Signal Transduction -- physiology
|
|
Molecular Targeted Therapy -- methods
|
|
Medical Oncology
|
|
Biochemical markers
|
|
Cancer -- Molecular diagnosis
|
|
Oncology
|
| Form |
Electronic book
|
| Author |
Badve, Sunil, editor.
|
|
Kumar, George Louis, 1966- editor.
|
| LC no. |
2018958983 |
| ISBN |
3319952285 |
|
9783319952284 |
|
